Andreas Kalmes

Andreas has overseen Revalesio’s clinical program in ALS since 2015. He has worked in drug development in the biotech and pharmaceutical industry since 2001, holding group leader positions at Amgen and Immunex prior to joining Revalesio in 2010. Andreas received his Ph.D. degree in 1993 from the University of Mainz in Germany and was a senior research fellow at the University of Washington in Seattle from 1997 to 2001.